Over the last 20 years there has been major innovation in treatment of Inflammatory Bowel Disease (IBD) catalyzed due the biologics that offer greater on target selectivity than aminosalicylates, corticosteroids or immunosupressants.
These biologic drugs need to be injected or infused but patients with a chronic disease prefer the convenience of an oral drug that allows them to maintain an active lifestyle.
There has been a drought in innovation. It’s been decades since patients have had new classes of oral drugs.
A clear opportunity and gap that Morphic Therapeutic intends to fill.